Knott David M Jr Purchases 17,783 Shares of Liquidia Corporation $LQDA

Knott David M Jr increased its holdings in Liquidia Corporation (NASDAQ:LQDA) by 19.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 107,783 shares of the company’s stock after acquiring an additional 17,783 shares during the quarter. Liquidia makes up about 1.0% of Knott David M Jr’s investment portfolio, making the stock its 20th largest position. Knott David M Jr’s holdings in Liquidia were worth $2,451,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Whitcomb & Hess Inc. raised its holdings in shares of Liquidia by 2.0% in the 3rd quarter. Whitcomb & Hess Inc. now owns 28,385 shares of the company’s stock valued at $645,000 after purchasing an additional 558 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its position in shares of Liquidia by 24.0% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after purchasing an additional 1,200 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Liquidia during the third quarter valued at approximately $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Liquidia by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after purchasing an additional 1,700 shares in the last quarter. Finally, Significant Wealth Partners LLC increased its holdings in Liquidia by 16.8% during the third quarter. Significant Wealth Partners LLC now owns 13,131 shares of the company’s stock valued at $299,000 after buying an additional 1,891 shares during the period. 64.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Wells Fargo & Company boosted their price objective on shares of Liquidia from $31.00 to $44.00 and gave the stock an “overweight” rating in a research note on Friday. Needham & Company LLC increased their target price on Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a report on Thursday, January 22nd. Zacks Research cut Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. Finally, Lifesci Capital raised Liquidia to a “strong-buy” rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Insider Activity

In other Liquidia news, insider Scott Moomaw sold 20,533 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $768,550.19. Following the completion of the sale, the insider owned 154,514 shares of the company’s stock, valued at approximately $5,783,459.02. This trade represents a 11.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajeev Saggar sold 21,142 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $791,345.06. Following the sale, the insider owned 176,883 shares in the company, valued at $6,620,730.69. The trade was a 10.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 212,534 shares of company stock worth $7,964,719 over the last quarter. Company insiders own 26.50% of the company’s stock.

Liquidia Trading Up 4.4%

NASDAQ:LQDA opened at $36.03 on Friday. The stock has a market capitalization of $3.13 billion, a price-to-earnings ratio of -43.41, a PEG ratio of 0.60 and a beta of 0.52. Liquidia Corporation has a 52 week low of $11.26 and a 52 week high of $46.67. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The firm has a 50 day moving average of $37.10 and a 200 day moving average of $30.89.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.18). The firm had revenue of $92.02 million during the quarter. Liquidia had a negative return on equity of 237.79% and a negative net margin of 43.53%.The business’s revenue for the quarter was up 3072.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).